Anticoagulation therapy during pregnancy and puerperium

  • Sultana Habib National Institute of Cardiovascular Diseases (NICVD), Karachi (Pakistan)
  • Amin M Khuwaja National Institute of Cardiovascular Diseases (NICVD), Karachi (Pakistan)
  • Najma Amjad National Institute of Cardiovascular Diseases (NICVD), Karachi (Pakistan)
Keywords: Anticoagulant drugs, Venous thromboembolism, Platelet aggregation inhibitors, Heparin, Warfarin

Abstract

Thrombotic complications are three to five times higher than non-pregnant women and even in pregnant women anticoagulant therapy is indicated for the prevention and treatment of a number of cardiac and non-cardiac conditions. This therapy may have some serious concerns for the safety of the new life in the womb of the mother or to the mother if she has to undergo some type of operative delivery. Whether, anti-coagulation is achieved with oral or injectable drugs, we must be fully aware of the pharmacology, and the means to control the undesirable side effects.

Citation: Habib S, Khuwaja AM, Amjad N. Anticoagulation therapy during pregnancy and puerperium. Anaesth Pain & Intensive Care 2014;18(4):415-418

Published
01-28-2019
How to Cite
Habib, S., Khuwaja, A. M., & Amjad, N. (2019). Anticoagulation therapy during pregnancy and puerperium. Anaesthesia, Pain & Intensive Care, 415-418. Retrieved from https://apicareonline.com/index.php/APIC/article/view/393
Issue
Vol.18 No.4(2014): October-December
Section
Special Articles